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Chemotherapy and radiotherapy commonly damage DNA
and trigger p53-dependent apoptosis through intrinsic
apoptotic pathways. Two unfortunate consequences of this
mechanism are resistance due to blockade of p53 or
intrinsic apoptosis pathways, and mutagenesis of non-
malignant surviving cells which can impair cellular
function or provoke second malignancies. Death ligand-
based drugs, such as tumor necrosis factor-related
apoptosis inducing ligand (TRAIL), stimulate extrinsic
apoptotic signaling, and may overcome resistance to
treatments that induce intrinsic apoptosis. As death
receptor ligation does not damage DNA as a primary
mechanism of pro-apoptotic action, we hypothesized that
surviving cells would remain genetically unscathed,
suggesting that death ligand-based therapies may avoid
some of the adverse effects associated with traditional
cancer treatments. Surprisingly, however, treatment with
sub-lethal concentrations of TRAIL or FasL was
mutagenic. Mutations arose in viable cells that contained
active caspases, and overexpression of the caspase-8
inhibitor crmA or silencing of caspase-8 abolished
TRAIL-mediated mutagenesis. Downregulation of the
apoptotic nuclease caspase-activated DNAse (CAD)/
DNA fragmentation factor 40 (DFF40) prevented the
DNA damage associated with TRAIL treatment.
Although death ligands do not need to damage DNA in
order to induce apoptosis, surviving cells nevertheless
incur DNA damage after treatment with these agents.
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Introduction
Conventional chemotherapy agents interfere with DNA
replication and therefore primarily target dividing cells,
by either preventing nucleotide biosynthesis, cross-
linking DNA, preventing the maintenance of DNA
topology or interfering with microtubule dynamics.
These processes exert anti-tumor effects by inducing
apoptosis, senescence and/or mitotic catastrophe. The
pro-apoptotic action of many chemotherapeutic agents
involves the generation of DNA damage, whose recogni-
tion activates stress kinases that phosphorylate p53 and
prevent its proteosomal degradation (Meulmeester and
Jochemsen, 2008). p53 induces pro-apoptotic proteins
such as PUMA p53-upregulated modulator of apoptosis
(PUMA) (Nakano and Vousden, 2001; Yu et al., 2001),
which participates in the mitochondrially-controlled
‘intrinsic’ apoptosis pathway (Yu and Zhang, 2008).
This cell death pathway is regulated by Bcl-2 family
proteins (Brunelle and Letai, 2009) and is executed by a
molecular machinery including cytochrome-c, Apaf-1 and
caspases-9, -3 and -7 (Riedl and Salvesen, 2007). Active
downstream caspases cleave a variety of cellular
substrates, leading to the demolition of the cell (Timmer
and Salvesen, 2007). Inhibitor of caspase-activated
DNAse (ICAD) (also known as DNA fragmentation
factor 45; DFF45) is one important caspase substrate
(Enari et al., 1998, Liu et al., 1998). Its cleavage permits
caspase-activated DNAse (CAD)/DNA fragmentation
factor 40 (DFF40) to fragment chromosomal DNA
(Enari et al., 1998; Liu et al., 1998).
Although chemotherapy drugs can cure the majority
of patients diagnosed with particular types of cancer
(Evens et al., 2008; Jeha, 2009), many cancers tend to
respond poorly, and better treatments are needed for
these tumors (Winer et al., 2009). Defects in p53 or its
relatives, mutations in components of the intrinsic
apoptosis pathway or alterations in their expression,
can contribute to chemotherapy insensitivity (Coultas
and Strasser, 2003; Muller et al., 2006), so treatments
that can bypass p53 and the intrinsic pathway may be
effective in treating unresponsive cancers. Another
challenge for improving cancer treatment is minimizing
adverse effects of anti-neoplastic therapies. In addition
to well-documented acute toxic effects of chemotherapy
and radiotherapy, cancer survivors sometimes suffer so-
called ‘late effects’ that can manifest years into decades
after successful treatment. These include cardiac, endo-
crine and central nervous system symptoms, as well as
second malignant neoplasms (Dickerman, 2007; Mea-
dows et al., 2009). These new cancers probably result
from the genotoxic effects of chemotherapy or radio-
therapy on normal cells (Rice et al., 2004).
A major recent focus of development of new cancer
therapies has been the extrinsic death receptor apoptosis
pathway, particularly drugs based on tumor necrosis
factor-related apoptosis inducing ligand (TRAIL, also
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and related agents offer potential advantages over
conventional chemotherapeutic drugs both in terms of
efﬁcacy and minimizing side effects. TRAIL is a type-II
membrane protein with an extracellular carboxyl-
terminal domain (amino acids 114 to 281) constituting
the receptor-binding site (Wiley et al., 1995; Pitt et al.,
1996). It induces the extrinsic apoptosis pathway by
ligating death receptors (DR4/TRAIL-R1 and DR5/
TRAIL-R2) that promote recruitment of FADD,
caspase-8 and/or caspase-10 to form the ‘death-inducing
signaling complex’ (DISC) (Ashkenazi, 2008). Caspases-
8 and/or -10 are activated within the DISC. In ‘type-I’
cells, these are able to directly cleave and activate
executioner caspases-3 and -7; in ‘type-II’ cells, mito-
chondrial ampliﬁcation of this signal is required for
apoptosis to proceed (Knight et al., 2004; Vogler et al.,
2008). Because TRAIL induces apoptosis through a
distinct pathway from classical anti-cancer treatments, it
promises to bypass blocks in intrinsic apoptotic path-
ways that render some tumor cells resistant to che-
motherapy and/or radiotherapy. Pre-clinical studies
revealed that ‘soluble’ trimeric TRAIL, consisting of
the ligand’s extracellular domain complexed with zinc,
showed a high degree of speciﬁcity for tumor cells
relative to normal cells (Ashkenazi et al., 1999; Hao
et al., 2004; Lawrence et al., 2001), however cross-linked
and tagged formulations of TRAIL induced apoptosis
in hepatocytes (Jo et al., 2000; Lawrence et al., 2001;
Ganten et al., 2006; Ashley et al., 2008) and various
other normal cells (Ashley et al., 2008; Leverkus et al.,
2000; Nitsch et al., 2000). Soluble TRAIL and agonistic
antibodies targeting its pro-apoptotic receptors have
shown robust anti-tumor activity in animal models
(Chuntharapai et al., 2001; Kelley et al., 2001), and
encouraging results are emerging from early phase
clinical trials (Ashkenazi, 2008; Holoch and Grifﬁth,
2009; Mahalingam et al., 2009).
This study was designed to investigate the impact of
TRAIL exposure on surviving cells. We reasoned that,
as TRAIL induces apoptosis through a mechanism that
does not require damage to DNA, cells that survive
TRAIL treatment would be unlikely to bear mutations
that could provoke late effects such as second malig-
nancies in a clinical setting. We, therefore, compared the
mutagenic capacity of sub-lethal doses of TRAIL and
conventional chemotherapy drugs, using two commonly
employed assays for DNA damage. The hypoxanthine-
guanine phosphoribosyltransferase (HPRT) enzyme
participates in purine salvage pathways. HPRT-proﬁ-
cient cells are killed by the purine analog 6-thioguanine
(6-TG), but cells bearing HPRT loss-of-function muta-
tions survive and form colonies. Hence, the number of
6-TG-resistant colonies after treatment with a drug such
as TRAIL provides a readout of the mutational capacity
of that drug (DeMars, 1971). Generation of double-
stranded DNA breaks leads to activation of protein
kinases including ataxia-telangiectasia mutated (ATM),
whose downstream targets include histone 2AX
(H2AX). H2AX phosphorylation (gH2AX) covers large
regions of the chromosome surrounding each lesion,
hence levels of gH2AX reﬂects the degree of DNA
damage (Kuo and Yang, 2008; Watters et al., 2009). To
our surprise, these assays revealed that TRAIL treat-
ment did damage the DNA in surviving cells. This
genotoxic effect was caspase-8- and CAD-dependent.
Results
Increased mutation frequency in cells treated with TRAIL
and FasL
In this study, we compared the potential of TRAIL,
FasL and known mutagens to cause acute cell death,
impair clonogenic survival and generate mutations in
surviving cells. To monitor cell death, propidium iodide-
uptake and clonogenicity assays were performed, in
which the cells were tested after 1 or 24h exposure.
Resistance to 6-TG was used as a readout of mutations
in the HPRT locus. Ethane methyl sulfonate (EMS) is a
well-studied mutagen (Gocke et al., 2009) and was used
as a positive control drug. Treatment of the LN18
glioblastoma cell line with EMS decreased the cells’
clonogenic survival and elicited a corresponding in-
crease in the formation of 6-TG resistant colonies
(Figure 1a), implying the presence of mutations in the
HPRT locus. Cisplatin is a commonly used chemother-
apy drug, which cross-links DNA and causes DNA
damage. It showed a similar effect as EMS—an increase
in mutation frequency with decreasing cell survival
(Figure 1b). TRAIL induces apoptosis through activa-
tion of the extrinsic pathway, a mechanism thought not
to be involved in DNA damage. Nevertheless, LN18
cells that were treated with a cross-linked TRAIL
formulation or a soluble form showed an increase in
mutation frequency at the HPRT locus, along with
decreased cell survival (Figures 1c and d).
To determine whether this apparent mutagenic
property is speciﬁc to TRAIL, or may be a general
feature of death ligands, we monitored the impact of
FasL exposure on viability and mutation rate in LN18
cells. As for TRAIL, the pro-apoptotic effect of FasL
was accompanied by emergence of 6-TG-resistant clones
(Figure 1e), implying that it too induces mutations in
surviving cells.
These viability and mutagenesis assays were repeated
in a second cell type: mouse embyronic ﬁbroblasts
(MEFs). EMS exerted the same effect in MEFs as in
LN18 cells: mutation frequency increased with decreas-
ing clonogenic cell survival (Figure 2a). As in LN18
cells, cisplatin provoked a dose-dependent impact on
clonogenic survival and increase in mutation frequency
in MEFs (Figure 2b).
MEF cells were strikingly resistant to the toxic effects of
cross-linked TRAIL. After a 1h exposure, no difference
c o u l db eo b s e r v e di nc l o n o g e n i cs u r v i v a lb e t w e e nu n -
treated and TRAIL-treated cells. After 24h exposure, a
decrease in clonogenic potential was observed only at the
highest dose (1mg/ml). 6-TG-resistant colonies emerged
after treatment with sub-lethal doses of cross-linked
TRAIL, and mutation frequency increased with exposure
to increasing concentrations (Figure 2c).
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by soluble TRAIL at the doses used (up to 300ng/ml),
but an increase in mutation frequency could be detected
with increasing doses (Figure 2d). An increase in MEF
cells bearing HPRT mutations was also detected
following exposure to FasL, whereas the cells’ clono-
genic potential remained unchanged (Figure 2e). These
data show that TRAIL and FasL can stimulate
mutagenesis in contexts in which these agents do not
induce apoptosis. This argues against the possibility that
the appearance of 6-TG-resistant clones following
death-ligand treatment merely reﬂects selection for a
pre-existing sub-population that is resistant to death
induced by both 6-TG and death ligands.
The highest mutation frequency stimulated by
TRAIL was experienced by LN18 cells exposed to
300ng/ml of soluble TRAIL (Figure 3a). This treatment
abolished the clonogenic potential of 93% of the cells,
and 20.6% of the remaining viable cells formed colonies
in the presence of 6-TG, implying that they had
sustained loss-of-function mutations in the HPRT locus.
In comparison, incubation with 1.6mg/ml cisplatin
prevented clonogenic growth of 75% of LN18 cells,
and 8.1% of the cells that retained clonogenic potential
acquired HPRT mutations. In MEF cells, cisplatin was
more mutagenic than either formulations of TRAIL at
the doses analyzed (Figure 3b).
Double-stranded DNA damage in cells treated with
TRAIL or cisplatin
To conﬁrm that the development of 6-TG-resistant
clones following TRAIL treatment did reﬂect mutagen-
esis (rather than an alteration in nucleotide biosynth-
esis), we used a second, independent technique to
monitor DNA damage. Phosphorylated H2AX proteins
surrounding double-stranded breaks promotes the
accumulation of DNA repair factors at the site of
damage. Flow cytometric quantitation of H2AX phos-
phorylation provides a robust and sensitive measure of
DNA damage (Watters et al., 2009). Exposure to cross-
linked TRAIL provoked a dose- and time-dependent
increase in the proportion of MEF and LN18 cells
containing phosphorylated H2AX (Figures 4a and b).
Treatment with the soluble form of TRAIL triggered
gH2AX in fewer cells (Figures 4c and d). Incubation
with cisplatin, stimulated substantial H2AX phospho-
rylation in MEF cells (Figure 4e), but much less in LN18
cells (Figure 4f). It has been previously noted that
gH2AX foci form in cisplatin-treated cells only following
Figure 1 TRAIL or FasL treatment of LN18 cells provokes
generation of 6-TG-resistant colonies. LN18 cells were incubated
with various doses of ethane methyl sulfonate (a), cisplatin (b),
cross-linked TRAIL (c), soluble TRAIL (d) or Fas ligand (e), either
for 24h or for 1h followed by 23h incubation in normal media.
Propidium iodide uptake (a–d) or clonogenicity assays (a–e) were
then performed, as outlined in the Materials and methods. Cells
were exposed to selected doses of the drugs for 1h for HPRT
mutagenicity assays. The left Y-axis and black and gray lines depict
survival as measured in acute cell death and clonogenicity assays.
The right Y-axis and white columns show the number of 6-TG-
resistant colonies in mutational assays. Error bars indicate
standard errors of the means from either three (a, b, e), four (c)
or ﬁve (d) independent experiments.
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Schwager et al., 2005; Olive and Banath, 2009), so the
lower proportion of gH2AX-positive LN18 cells relative
to MEF cells may simply reﬂect differences in prolifera-
tion rates.
The mutagenic effect of TRAIL requires caspase-8
Stable MEF clones expressing wild-type crmA or an
inactive crmA mutant (Ekert et al., 1999), or bearing an
empty vector (pEF) were generated to investigate
whether crmA inhibition of caspase-8 could block
TRAIL-induced apoptosis and/or mutagenesis. The
presence of plasmid DNA in the empty vector clones
was conﬁrmed by PCR (Figure 5a) and expression of
wild-type and mutant crmA was visualized by western
blot (Figure 5b). Functionality of the stable crmA
transfectants was tested by transiently transfecting these
and parental MEF cells with a caspase-8 expression
plasmid. Overexpression of caspase-8 induced apoptosis
in parental MEFs and the crmA mutant MEF clones,
but the wild-type crmA MEF clones were resistant to
caspase-8 induced death (Figure 5c). As expected,
transient co-transfection of a crmA plasmid together
with the caspase-8 construct failed to kill parental MEFs
and the crmA mutant MEF cell lines (Figure 5c). All
stable transfectant lines maintained equivalent clono-
genic potential following exposure to cross-linked
TRAIL for 1h (Figure 5d). Parental MEFs, crmA
mutant clones and empty vector transfectants formed 6-
TG-resistant colonies following TRAIL treatment in a
dose-dependent manner, but the crmA-expressing clones
only developed background levels of 6-TG-resistant
colonies, regardless of TRAIL exposure (Figure 5e).
Cisplatin provoked clonogenic cell death in crmA, crmA
mutant, pEF clones and in the parental cell line
(Figure 5f). The mutagenic effect of cisplatin persisted
in the presence of wild-type crmA and was curiously
enhanced by expression of mutant crmA (Figure 5g).
The effect of crmA expression on TRAIL-induced
DNA damage was also investigated in LN18 cells. Co-
transfection with a green ﬂuorescent protein expression
plasmid revealed that transient transfection frequencies
of around 80% were consistently achieved in this cell
line, obviating the need to generate stable transfectants.
As in MEF cells, expression of wild-type crmA
protected LN18 cells from apoptosis induced by
caspase-8 overexpression (Figure 6a). Signiﬁcantly fewer
LN18 cells expressing wild-type crmA bore phosphory-
lated H2AX than cells transfected with either the crmA
mutant plasmid or empty vector (Figure 6b). The
Figure 2 TRAIL or FasL treatment of mouse embryo ﬁbroblast
(MEF) cells provokes generation of 6-TG-resistant colonies. MEF
cells were incubated with various doses of ethane methyl
sulphonate (a), cisplatin (b), cross-linked TRAIL (c), soluble
TRAIL (d) or Fas ligand (e), for 1hr or 24h, prior to propidium
iodide uptake (a–d) or clonogenicity assays (a–e). Cells were
exposed to selected doses of the drugs for 1h for HPRT
mutagenicity assays. The left Y-axis and black and gray lines
depict survival as measured in acute cell death and clonogenicity
assays. The right Y-axis and white columns show the number of 6-
TG-resistant colonies in mutational assays. Doses, which failed to
generate any 6-TG-resistant colonies are labeled ‘no col’. Error
bars indicate standard errors of the means from either three
(a, b, e), four (c) or ﬁve (d) independent experiments.
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transfected with the crmA plasmid probably represents
the sub-population (B20% of cells) which were not
transiently transfected. In contrast, crmA expression
had no effect on cisplatin-mediated cell death nor the
modest ability of cisplatin to stimulate gH2AX in this
cell line (Figure 6b).
The above results imply that a crmA-sensitive
protease is required for TRAIL to stimulate DNA
damage. Although caspase-8 is the obvious candidate
for this protease, these data could not rule out the
possible involvement of other proteases susceptible to
crmA inhibition, like caspase-1 (Komiyama et al., 1994).
To directly test the requirement for caspase-8 in TRAIL
mutagenesis, we downregulated its expression in MEF
cells and monitored gH2AX formation after TRAIL
treatment. Caspase-8 downregulation (Figure 7a) was
mirrored by a corresponding decrease in the proportion
of cells bearing phosphorylated H2AX (Figure 7b),
whereas silencing of glyceraldehyde 3-phosphate dehy-
drogenase had no such effect (Figure 7b).
CAD involvement in TRAIL-induced DNA damage
The data above imply that treatment with TRAIL (or
FasL) provokes mutagenesis in surviving cells, in a
caspase-8 dependent manner. One potential mechanism
by which death receptor signaling could stimulate
mutagenesis would be caspase-mediated activation of
the DNase CAD/DFF40. Activated caspases-3 and -7
can cleave ICAD/DFF45, which keeps CAD inactive
and (at least in some cells) sequestered in the cytosol
(Enari et al., 1998; Liu et al., 1998). When ICAD is
cleaved, CAD becomes activated and can translocate to
the nucleus to fragment cellular DNA (Widlak and
Garrard, 2005). We examined the effect of TRAIL or
cisplatin treatment on caspase activation and CAD
translocation (as a measure of activation) in MEF cells.
Activation of executioner caspases-3 and -7 was
investigated using the ﬂuorescent inhibitor SR-DEVD-
FMK. Localization of CAD was measured by ﬂuores-
cence microscopy. CAD was localized in the nucleus in
approximately 24% of TRAIL-treated cells, compared
with 13% of untreated cells (Figures 8a and b).
Approximately 67% of cisplatin-treated cells bore
nuclear CAD (Figures 8a and b). Co-staining with the
CAD antibody and ﬂuorescent caspase inhibitor re-
vealed that CAD was nuclearly localized in 78% of cells
containing active caspases (Figures 8a and b).
To assess whether CAD and caspase activation
correlated with mutagenesis, TRAIL-treated MEF cells
were sorted into SR-DEVD-FMK positive and negative
populations and cultured. After a week’s culturing,
clonogenic and HPRT mutagenesis assays were per-
formed with each sub-population. There was no
difference in clonogenic potential between SR-DEVD-
FMK positive and SR-DEVD-FMK negative cells,
but the mutation frequency was 10-fold higher in
SR-DEVD-FMK positive cells (Figure 8c).
To directly assess the importance of CAD in TRAIL-
induced mutagenesis, small interfering (si)RNA was
used to downregulate CAD in MEF cells (Figure 8d).
The proportion of MEF cells containing phosphorylated
H2AX decreased with increased concentrations of
silencer RNA (Figure 8e).
Figure 3 Mutation frequencies of TRAIL and cisplatin. Mean mutation frequencies of LN18 (a) and mouse embryo ﬁbroblast (b)
cells are expressed as the percentage of clonogenically competent cells that generated 6-TG-resistant colonies. The X-axes show the
doses analyzed (in log scale). Only doses that enabled the clonogenic survival of more than ﬁve cells per experiment were included in
this analysis.
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TRAIL signaling and its ability to activate extrinsic cell
death has been extensively characterized, but the ability
of TRAIL to cause mutations has not been explored to
date. As TRAIL activates an apoptotic pathway that
does not require recognition of DNA damage, unlike
many conventional chemotherapeutic agents, we sought
to determine whether TRAIL signaling would cause
permanent damage to the genomes of surviving cells. It
has previously been shown that EMS and cisplatin,
drugs that create DNA adducts, can cause DNA
damage and mutations (Rabik and Dolan, 2007; Gocke
et al., 2009). We have conﬁrmed those results in human
and murine cell lines, using a conventional HPRT assay
and by detection of phosphorylated H2AX. These
techniques and cells were used to evaluate the mutagenic
capacity of two formulations of TRAIL: cross-linked
(‘superkiller’) TRAIL and the extracellular portion
(‘soluble’ TRAIL). Unlike cross-linked preparations,
soluble TRAIL has been previously shown to be non-
toxic to normal human cells (Ashkenazi et al., 1999),
which would give this formulation an advantage in
cancer therapy. To our surprise, both formulations
generated mutations in surviving cells. The mutagenic
capacity of both preparations of TRAIL was dose-
dependent, evident using two independent assays in two
cell lines, and manifested in MEF cells at sub-lethal
concentrations. Additional research will be needed to
explore the susceptibility of additional normal and
cancerous cell types to the genotoxic effects of TRAIL.
Fas ligand, another death ligand that activates
extrinsic apoptosis signaling, also showed mutagenic
potential. This argues against the possibility that
TRAIL receptors possess a unique mutagenic signaling
mechanism, and implicates molecules downstream of
death receptors in transmitting the mutagenic signal.
Expression of wild-type (but not mutant) crmA, or
siRNA silencing of caspase-8 abolished the mutagenic
effect of TRAIL, indicating that TRAIL-induced
mutagenesis is caspase-8 dependent. Apoptotic stimuli
provoke caspase-dependent cleavage of ICAD, allowing
CAD to fragment DNA during apoptosis (Widlak,
2000). It occurred to us that low levels of CAD
Figure 4 TRAIL treatment stimulates phosphorylation of H2AX. The right Y-axes and gray lines show the proportion of MEF cells
(a, c, e) or LN18 cells (b, d, f) bearing phosphorylated H2AX after 1 or 5h exposure to cross-linked TRAIL (a, b), soluble TRAIL
(c, d) or cisplatin (e, f). The left Y-axes and black lines represent the percentage of viable cells after same drug exposures. Error bars
indicate s.e.m. from three independent experiments.
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underlie TRAIL’s genotoxic effect. Consistent with this
model, an increase in cells bearing nuclear CAD was
observed following exposure to a non-lethal dose of the
drug, compared with those untreated cells. Caspases
were activated in TRAIL-treated cells bearing nuclear
CAD. TRAIL-treated cells containing activated cas-
pases at the time of isolation initially proliferated
somewhat slower after sorting, but when reseeded the
clonogenicities of the two populations were similar. One
explanation for the slow start could be that DNA was
damaged in cells bearing active caspases, so they may
have arrested and recommenced cycling after their DNA
was repaired. Viable TRAIL-treated cells in which
caspases had been activated showed a ten-fold increase
in mutation frequency compared with caspase-negative
Figure 5 CrmA expression prevents the formation of 6-TG-resistant mouse embryo ﬁbroblast (MEF) colonies following TRAIL
treatment. MEF cells were stably transfected with empty vector (pEF), a wild-type FLAG-tagged crmA expression plasmid or a loss-
of-function FLAG-crmA expression plasmid. Genomic DNA from pEF clones was ampliﬁed using PCR (a). Products of reactions
containing either no template or 100ng of plasmid are denoted ‘pos cont’ and ‘neg cont’ respectively. CrmA expression was analyzed
using anti-FLAG immunoblotting, relative to a GAPDH loading control (b). (c) The phenotypes of crmA wild-type and mutant clones
were tested by transiently transfecting the clones with empty vector (pEF), crmA and/or caspase-8 expression plasmids (90% of
transfected DNA), along with a b-galactosidase expression plasmid (10%). The transfectants were stained with Xgal and the blue
(transfected) cells were scored visually for morphological characteristics of apoptosis. The proportions of each transiently transfected
plasmid are indicated under the graph, as are the stable clones into which this DNA was introduced. Clonogenic survival of each clone
was monitored following 1h exposure to cross-linked TRAIL (d) or cisplatin (f). Parental MEF cells and the indicated stable cell lines
were treated with cross-linked TRAIL(e) or cisplatin (g) for 1h then subjected to the HPRT mutational assay, and the 6-TG-resistant
clones that emerged were counted.
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spontaneous mutations. Although it was originally
assumed that cells bearing active caspases would be
destined to die, it is increasingly recognized that cells can
tolerate a degree of caspase activation without under-
going apoptosis (Abraham and Shaham, 2004), and this
study provides further evidence supporting that notion.
Our study has revealed that cells surviving exposure
to TRAIL sustain DNA damage through a caspase-8-
dependent mechanism. TRAIL-treated cells with active
caspases and nuclearly localized CAD showed markedly
higher mutation rates than cells with inactive caspases
and cytosolic CAD. This led us to postulate that TRAIL
causes mutagenesis in context involving caspase activa-
tion that is insufﬁcient to induce apoptosis, but
sufﬁcient to cleave ICAD and activate CAD, which
damages DNA (Figure 9). Consistent with this model,
downregulation of CAD protected TRAIL-treated cells
from DNA damage. Our data provide support for a
previous speculation that sub-lethal apoptotic signaling
may burden surviving cells with mutations caused by
misrepair of DNA damage elicited by apoptotic
nucleases (Vaughan et al., 2002). CAD cleavage of
DNA generates blunt (or nearly blunt) double-stranded
breaks (Widlak et al., 2000). These would probably be
repaired in surviving cells by previously characterized
mechanisms including non-homologous end-joining,
which is often non-conservative and can introduce
mutations (Hartlerode and Scully, 2009). If the muta-
genic capacity of TRAIL we have observed is subse-
quently conﬁrmed in vivo, the potential for adverse
effects resulting from mutations in surviving normal
cells should be considered if TRAIL-based drugs
become clinically used. Further work will be needed to
determine if other anti-cancer agents targeting apoptosis
pathways can also provoke mutagenesis in surviving
cells.
Materials and methods
Cell lines and materials
The glioma cell line LN18 was purchased from ATCC
(Manassas, VA, USA). SV-40 transformed MEF were kindly
provided by Anissa Jabbour (Jabbour et al., 2009). All cells
were cultured in Dulbecco’s modiﬁed Eagle medium high
glucose (Invitrogen, Carlsbad, CA, USA) containing 10% fetal
calf serum (Invitrogen). Drugs used in this study were cisplatin
(Mayne Pharma, Mulgrave, Victoria, Australia), EMS (Sigma
Aldrich, St Louis, MO, USA), 6-TG (Sigma Aldrich), Super-
killer (cross-linked) TRAIL (Alexis Biochemicals, Lausen,
Switzerland), recombinant human (soluble) TRAIL (Chemicon,
Figure 6 CrmA expression prevents TRAIL-induced DNA damage in LN18 cells. (a) LN18 cells were transiently transfected with the
indicated plasmids (90% of transfected DNA), along with a b-galactosidase expression plasmid (10%). The transfectants were stained
with Xgal and the blue (transfected) cells were scored visually for apoptosis based on morphological criteria. The percentage of the
transiently transfected plasmids are indicated under the graph. (b) LN18 cells were transiently transfected with an empty vector (pEF)
or plasmids encoding wild-type or mutant crmA, then incubated with the indicated doses of cross-linked TRAIL, soluble TRAIL or
cisplatin for 5h. The proportions of cells bearing phosphorylated H2AX were quantitated by ﬂow cytometry. Error bars indicate
standard errors of the means from three independent experiments.
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Biochemicals). The following antibodies were used: anti-
FLAG antibody (Sigma Aldrich, clone M2), anti-GAPDH
(Chemicon, clone 6C5), anti-CAD (ProSci, Poway, CA, USA;
#2007), anti-caspase-8 (ProSci, #3475), anti-H2AX (Ser 139)
(Cell Signaling, Danvers, MA, USA; clone 20E3), goat anti-
mouse-HRP (Sigma Aldrich), goat anti-rabbit FITC antibody
(Chemicon) and donkey anti-rabbit-HRP (Amersham/GE
Healthcare, Rydalmere, NSW, Australia).
Plasmids
The pEF, pEF-FLAG-crmA and CMV-LacZ plasmids have
been previously described (Hawkins et al., 1996), as was pEF-
FLAG-crmA
T291R (Ekert et al., 1999). To generate pEF-koz-
caspase-8, the coding region of caspase-8 was ampliﬁed using
primers 1 and 2, and then the product was cut with BamHI and
XbaI and inserted into pEF cut with BamHI and XbaI.
pEGFP-N1 (Clontech, Mountain View, CA, USA) was used to
monitor transfection efﬁciency.
Transfections
Stable MEF transfectants were made using FuGENE HD
transfection reagent (Roche, Basel, Switzerland) and selected
in 30mg/ml puromycin (Sigma Aldrich). Expression was
conﬁrmed by immunoblotting as previously published (Ashley
et al., 2008). The presence of the empty pEF plasmid was
conﬁrmed by PCR ampliﬁcation using primers 3 and 4 and
Taq polymerase (Applied Biosystems, Mulgrave, Victoria,
Australia). Genomic DNA was extracted from MEFs using the
DNeasy Tissue Kit (Qiagen, Doncaster, Victoria, Australia)
according to manufacturer’s instructions. Thirty cycles were
used to amplify MEF pEF cDNA, according to the following
protocol: denaturation (30s, 941C), annealing (30s, 551C) and
extension (1min, 721C). LN18 cells were transiently trans-
fected using Lipofectamine Plus (Invitrogen). Transfection
efﬁciency was monitored by performing parallel transfections
in which pEGFP-N1 constituted 10% of the transfecting DNA
and analyzing the proportion of green cells by ﬂow cytometry
using a FACSCanto (BD Biosciences, San Jose, CA, USA).
Transient transfection efﬁciencies for LN18 cells were always
greater than 79%. To downregulate gene expression, MEF
cells were transfected with X-tremeGENE siRNA transfection
reagent (Roche) according to manufacturer’s instructions.
Oligonucleotides
1: 50GCGGGATCCGCCATGGACTTCAGCAGAAATCT
TTATG-30
2: 50-GCTCTAGACTAATCAGAAGGGAAGACAAG-30
3: 50-GAGACTGAAGTTAGGCCAGCTTGGC-30
4: 50-CAGCTCTGGCCACCTCTCCTTGTCC-30
Cell survival assays
Cells were incubated with drugs for 1 and 24h. Propidium
iodide-uptake assays were used to assess acute cell death. Ten
thousand cells were pelleted and resuspended in propidium
iodide (1mg/ml in phosphate buffered-saline (PBS)) (Sigma
Aldrich) then analyzed using a FACS Canto (BD Biosciences).
For all ﬂow cytometry assays, identiﬁcation of positive
populations was achieved using a marker, which designated
1% of untreated cells as positive. For clonogenicity assays,
3000 cells were plated per well of a six-well plate and incubated
with drugs for 1 or 24h. After 6 days, cells were stained with
methylene blue (Sigma Aldrich) 1.25g/l in 50% methanol,
incubated for 5min and washed twice with water and the
numbers of colonies counted. CrmA function was tested by
transiently co-transfecting MEF or LN18 cells with koz-
caspase-8, pEF and/or pEF-FLAG-crmA (90%) and CMV-
LacZ (10%). A day after transfection, cells were treated with
TRAIL for 24h then stained with Xgal (Hawkins et al., 1996).
Survival of blue (transfected) cells was scored visually based on
morphological criteria, as previously described (Hawkins et al.,
1996).
HPRT assay
The HPRT assay was based on a previously published method
(Op het Veld et al., 1997). Brieﬂy, 10
6 cells were seeded per
150mm dish (three dishes per treatment). After culturing for 4
days, 10
6 cells were re-seeded in fresh 150mm dishes and
grown for an additional 4 days. Cells were seeded at 10
5 cells
Figure 7 Downregulation of caspase-8 prevents TRAIL-induced
DNA damage. MEF cells were transfected with the indicated
concentrations of siRNAs targeting caspase-8 or glyceraldehyde 3-
phosphate dehydrogenase then subjected to immunoblotting (a)o r
treated with 300ng/ml cross-linked TRAIL and assayed for H2AX
phosphorylation (b). The left Y-axis and black lines represent the
percentage of viable cells. The right Y-axis and gray lines show the
proportion of cells bearing phosphorylated H2AX. Error bars
indicate s.e.m. from three independent experiments.
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Oncogeneper 150mm dish (three dishes per treatment) in media
containing 6-TG (Sigma Aldrich); 20mg/ml for LN18 cells
and 0.6mg/ml for MEF cells. Colonies were stained with
methylene blue and counted after 18 days (LN18) or 13 days
(MEF).
DNA damage assay
Staining of gH2AX was performed according to a published
protocol (MacPhail et al., 2003), with following changes: cells
were exposed to drugs for 1 or 5h then labeled with anti-
H2AX and anti-rabbit FITC antibodies. After washing to
Figure 8 Caspase-activated CAD is required for TRAIL to provoke mutations in surviving cells. (a) Fluorescent microscopy was used
to investigate CAD localization and SR-DEVD-FMK binding, as a measure of caspase-3/7 activation, in untreated MEF cells or cells
incubated for 24h with cisplatin (5.4mg/ml) or cross-linked TRAIL (300ng/ml). The scale bar is 100mm. (b) The proportions of cells
bearing nuclear CAD or SR-DEVD-FMK ﬂuorescence after each treatment were counted. At least 250 cells were scored for each
treatment per experiment for untreated and TRAIL-treated samples; at least 100 cisplatin-treated cells were scored per experiment.
Error bars indicate s.e.m. from four, three or seven replicates of untreated, cisplatin-treated or TRAIL-treated cells respectively.
P-values were calculated using a Student’s t-test. (c) After exposure to 300ng/ml cross-linked TRAIL for 24h, SR-DEVD-FMK
positive and negative cells were ﬂow cytometrically sorted and their clonogenicity assayed following treatment with 300ng/ml cross-
linked TRAIL for 1h. SR-DEVD-FMK positive and negative sorted cells were also subjected to the HPRT mutational assay, and the
6-TG-resistant clones that emerged were counted. Error bars show the s.e.m. from six or nine independent experiments for
clonogenicity and mutagenicity experiments respectively. MEF cells were transfected with the indicated concentrations of small
interfering RNAs targeting CAD or GFP then (d) subjected to immunoblotting or (e) treated with 300ng/ml cross-linked TRAIL and
assayed for H2AX phosphorylation. The left Y-axis and black lines represent the percentage of viable cells. The right Y-axis and gray
lines show the proportion of cells bearing phosphorylated H2AX. Error bars indicate s.e.m. from three independent experiments.
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Oncogeneremove unbound antibodies, the cells were resuspended in PBS
containing propidium iodide (5mg/ml) to limit the analysis to
permeabilized intact cells (excluding cells with sub-G1 DNA
content). The gH2AX signals from these cells were analyzed
using the FACS Canto (BD Biosciences).
Cell sorting
MEF cells were exposed to 300ng/ml cross-linked-TRAIL for
24h. Caspase activity was determined by the red ﬂuorescent
caspase activity (SR-DEVD-FMK) assay (Neuromics, Edina,
MN, USA) performed according to manufacturer’s instruc-
tions. Cells were stained with SR-DEVD-FMK and propidium
iodide. Cells with disrupted membranes, cellular debris and
cell aggregates were eliminated using propidium iodide
staining intensity, light scatter and pulse-width parameters.
SR-DEVD-FMK positive single viable cells were sorted using
a MoFlo (Beckman Coulter, Brea, CA, USA) using a 1–2 drop
envelope and high purity sort logic. One thousand cells
were plated for clonogenicity assays and 10
5 cells used in
HPRT assays.
Fluorescence microscopy
MEF cells were incubated for 24h with 300ng/ml superkiller
TRAIL or with 5.4mg/ml. cisplatin, or normal media. The
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Figure 9 TRAIL-induced mutagenesis model. Death receptor ligation promotes formation of the death inducing signalling complex
(DISC) and activation of caspase-8, which then activates caspases-3 and/or -7. This can trigger apoptosis (a), through cleavage of
numerous cellular substrates including ICAD, whose cleavage provokes activation of CAD which fragments DNA. Data reported
herein suggest that in cells bearing only a small number of activated effector caspases, limited caspase-mediated ICAD proteolysis leads
to CAD activation and DNA cleavage, but not apoptosis (b). We suggest that inaccurate repair of these lesions creates mutations in
surviving cells.
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Oncogenefollowing day, the cells were washed with PBS and ﬁxed in 4%
fresh paraformaldehyde for 15min. Cells were washed again
with PBS three times. Cells were permeabilized by incubating
with 0.2% Triton X-100 in PBS for 5min. Cells were washed
for 30min in PBS 1% bovine serum albumin, then incubated
with CAD antibody 1:100 for 1h. Cells were washed in PBS
again three times then incubated in anti-rabbit FITC antibody
1:200 for 2h in the dark. Cells were washed with PBS
containing 1% bovine serum albumin for three times and 1:30
SR-DEVD-FMK reagent (Neuromics) was added and incu-
bated at 371C, 5% CO2 for 1h in the dark. Cells were washed
three times with PBS containing 1% bovine serum albumin.
Hoechst stain (10mg/ml) in PBS was added to cells and
incubated for 10min in the dark. Cells were washed with 0.2%
Triton X-100 in PBS three times before mounting the coverslip
onto a microscope slide for analysis by ﬂuorescent microscopy
using an Olympus B202 microscope (Olympus, Mt Waverley,
Victoria, Australia).
Small interfering RNA silencing
MEF cells were transfected using the following small interfer-
ing RNA constructs: CAD (sc-29872, Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA), caspase-8 (s63395, Applied
Biosystems), GFP (sc-45924, Santa Cruz Biotechnology) and
glyceraldehyde 3-phosphate dehydrogenase (s234321, Applied
Biosystems). Half of the transfected cells were used for
immunoblotting and the remaining were exposed to 300ng/
ml cross-linked TRAIL or 5.4mg/ml cisplatin for 5h, and
gH2AX assays performed.
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